Johnson & Johnson: RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO beyond lung ...
The Lancet

Identification and validation of an explainable early-stage chronic kidney disease prediction model: a multicenter retrospective study

aSchool of Artificial Intelligence and Information Technology, Nanjing University of Chinese Medicine, Nanjing, China bJiangsu Province Engineering Research Center of TCM Intelligence Health Service, ...
London South East

London open: FTSE falls as BP and StanChart slump; AstraZeneca rallies on results

(Sharecast News) - London stocks fell in early trade on Tuesday, dragged lower by weak performances from BP and Standard Chartered despite more gains in Asia, where the Nikkei rose 2.3% to close at ...
Labroots

Study Finds No Association Between CBD Use and Liver Damage

Australian researchers examined the use of cannabidiol (CBD) products by cancer patients to assess the risk to liver health. The findings published in the journal BMJ Supportive & Palliative Care ...